+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector



Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector



Human Gene Therapy 11(10): 1477-1488




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035489536

Download citation: RISBibTeXText

PMID: 10910144

DOI: 10.1089/10430340050057549


Related references

Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. Human Gene Therapy 3(6): 665-676, 1992

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood & Cancer 63(8): 1349-1356, 2016

A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. Journal of ImmunoTherapy 31(9): 812-819, 2008

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clinical Cancer Research 18(9): 2679-2686, 2012

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of Clinical Oncology 34(12): 1368-1375, 2016

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. European Journal of Cancer 50(1): 170-177, 2014

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology 24(3): 500-506, 2006

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. Mabs 5(5): 801-809, 2014

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Human Gene Therapy 9(9): 1303-1311, 1998

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatric Blood & Cancer 60(11): 1801-1808, 2013

Lymphotactin and IL-2 gene-modified allogeneic tumor vaccine in patients with refractory or relapsed neuroblastoma. Proceedings of the American Association for Cancer Research Annual Meeting (41): 633, March, 2000

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. Journal of Nuclear Medicine 53(7): 1155-1163, 2012

A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. Journal of Pediatric Hematology/Oncology 33(1): 25-30, 2011

A phase I study of nifurtimox in patients with relapsed/refractory neuroblastoma. Journal of Clinical Oncology 26(15_suppl): 2561-2561, 2016

Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric Blood & Cancer 64(8): -, 2017